Conference Proceedings

Integrative Analysis of the Genomic and Transcriptomic Landscape of Relapsed/Refractory Multiple Myeloma Patients Treated With Venetoclax in Combination With Bortezomib and Dexamethasone: Biomarker Analyses From the Phase 3 BELLINI Study

Michael E O'Dwyer, Andrew Spencer, Shaji K Kumar, Rakesh Popat, Philippe Moreau, Monique Dail, Muhammad Jalaluddin, Xiaoqing Yang, Xin Lu, Zheng Zha, Fengjiao Dunbar, Deeksha Vishwamitra, Christine Mantis, Amal Melhem-Bertrandt, Jeremy A Ross, Simon J Harrison

Blood | American Society of Hematology | Published : 2020


Background: Multiple myeloma (MM) is a clonal plasma cell malignancy characterized by a complex genomic landscape with molecular and clinical heterogeneity. Venetoclax (Ven) is a selective, potent, oral BCL-2 inhibitor currently under investigation as a potential targeted therapy for the treatment of relapsed/refractory (RR) MM. Using a next-generation sequencing (NGS)-based approach, the mutational landscape and gene expression profile (GEP) of patients (pts) with RRMM in BELLINI was evaluated for potential impact on observed clinical outcomes in key biomarker subgroups. Methods: BELLINI (NCT02755597) is a randomized, double-blind, multicenter Phase 3 study of bortezomib + de..

View full abstract